Stockscreener 앱 받기
182.85
0.18%
0.33
전일 마감가:
$182.52
열려 있는:
$182.71
하루 거래량:
1.89M
Relative Volume:
0.90
시가총액:
$283.57B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
54.91
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
-1.02%
1개월 성능:
-10.49%
6개월 성능:
+116.19%
1년 성능:
+171.69%
1일 변동 폭
$181.58
$183.55
1주일 범위
$180.00
$185.61
52주 변동 폭
$66.16
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
182.85 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
948.45 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.32 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
201.55 | 356.49B | 62.82B | 3.62B | 17.82B | 2.0331 |
NVS
Novartis Ag Adr
|
146.03 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca (AZN) officer Sharma Mani granted additional Ordinary Shares - Stock Titan
Darren Sissons' Past Picks: AstraZeneca, Canadian Pacific Kansas City & Linde Plc - BNN Bloomberg
AstraZeneca plc Stock (GB0009895292): Strong Quarterly Results and Improved Outlook Support Shares - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Strong quarterly results and improved guidance lift AZN shares - AD HOC NEWS
Fund Update: 25,553,763 ASTRAZENECA (AZN) shares added to Legal & General Group Plc portfolio - Quiver Quantitative
AstraZeneca Advances Respiratory And Oncology Portfolio Within FTSE 350 - Kalkine Media
AstraZeneca stock price forecast: GBX13,000 support holds as AZN edges lower - Traders Union
Alteogen posts weaker Q1 as Korea tech deals lag last year’s AstraZeneca windfallCHOSUNBIZ - Chosunbiz
AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit - Law360
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
AstraZeneca slides Thursday, underperforms market - MarketWatch
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026 - marketscreener.com
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks (JAZZ:NASDAQ) - Seeking Alpha
AstraZeneca PLC (NYSE:AZN) Q1 2026 Earnings Call Transcript - Insider Monkey
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
AstraZeneca stock edges higher as revenue surpasses forecasts at $15.29 billion - Traders Union
MSN Money - MSN
AstraZeneca Earnings Call: Oncology Strength, Pipeline Bets - TipRanks
AstraZeneca Advances Early Liver-Function Trial That Could Shape Dosing for Future AZN Drugs - TipRanks
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC Share PriceAZN, RNS News, Articles, Quotes, & Charts (LON:AZN) - Proactive Investors
Strong Results and Improved Guidance Lifted AstraZeneca PLC (AZN) - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Unpacking A 21% Potential Upside Opportunity - DirectorsTalk Interviews
AstraZeneca stock drops 2.88% as shares remain below recent trading averages - Traders Union
ASTRAZENECA : Bernstein reaffirms its Buy rating - marketscreener.com
Mixed FDA Votes On Truqap And Camizestrant Refocus AstraZeneca Oncology Risk - Yahoo Finance
Is AstraZeneca PLC (AZN) A Good Stock To Buy Now? - Insider Monkey
AstraZeneca invests £300 million in UK drug development sites - marketscreener.com
FTSE 100 Today Focus on BP plc (LSE:BP), Shell plc (LSE:SHEL) and AstraZeneca plc (LSE:AZN) - Kalkine Media
FIGURE 8 INVESTMENT STRATEGIES LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer - MSN
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
Alhambra Investment Management LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
Transamerica MSCI EAFE Index VP's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
Fidelity Sustainable International Equity Fund's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
AstraZeneca slides Friday, underperforms market - MarketWatch
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
AstraZeneca updates voting rights and admits new shares to London Stock Exchange - Investing.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors - CoinCentral
FDA advisory panel recommends AstraZeneca’s Truqap for PTEN-deficient prostate cancer - Investing.com Nigeria
FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo - Stock Titan
FDA panel supports AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient prostate cancer - Stock Titan
FTSE 100 drops in thin trading as NatWest, AstraZeneca weigh - Moneycontrol.com
AstraZeneca wins FDA AdCom backing for Truqap (AZN:NYSE) - Seeking Alpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters - Benzinga
State Street International Developed Equity Index Portfolio's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1 - Value The Markets
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
0.82%
자본화:
|
볼륨(24시간):